Hisoniazid R=rifampicin Z=pyrazinamide E=ethambutol S=streptomycin MDRDSTdrug sensitivity test 2HRZES/1HRZE/5HRE D D D Der Zauberberg Die Zauberfloete
|
|
- りさこ がうん
- 5 years ago
- Views:
Transcription
1 () Tuberculosis the Lancet, July2, 2011 H23.8 Stephen D Lawn: Alimuddin Zumla the Lancet, July2, 2011 HIV 2 Newsweek Newsweek 1950 X X A3aA3b X CT CT Felson 2010 WHO the Lancet (2010WHO, Treatment of tuberculosis guidelines4 th edition160 ) 1 2HRZE/4HR ( 2 HRZE HR ) 2HRZE/4HE strong evidence INH 2HRZE/4HER 1/23
2 Hisoniazid R=rifampicin Z=pyrazinamide E=ethambutol S=streptomycin MDRDSTdrug sensitivity test 2HRZES/1HRZE/5HRE D D D Der Zauberberg Die Zauberfloete Lindenbaum Der Lindenbaum 2/23
3 12 HIV HIV HIV RA TNF MDR:multidrug resistant MDR INH Rifampicin XDRextensively drug resistant XDR fluoroquinolone 3 amynoglycoside ( capreomycinkanamaycinamikacin ) MDR 50 XDR 5 HIV perfect storm KwaZulu Natal province HIV WHO 16 tuberculosis immune reconstitution disease KwaZuluNatal Blood River 3/23
4 Blood River 1834 KwaZuluNatal D m salvo 500m Blood River Blood River m 4/23
5 M tuberculosism africanumm bovis M microtim canetti pasteurisation M bovis 6 BCG 1921 Mycobacterium bovis() 1 BCG Bacillus Calmette-Guerin : Guerin e BCG variable BCG HIV transcriptomics messenger RNA transcript signature RNA sodium hydroxide LED MDRXDR LPAs(line probe assay) LPAs GenoType MTBDRplus GenoTypeMTBDRsl XDR LPAs 2008 WHO Hain Xpert MTB/RIF assay rifampicin /23
6 M tuberculosisbcg mycobacteria Quanti-FERON T-SPOT Quanti-FERON T-SPOT Nitroimidazole the Lancet, 50 the Lancet, 1. 4/ HIV 5 HIV DM 3 6. HIV 7. RA TNF D 9MDRmultidrug resistant INH rifampicin 10XDR fluoroquinolone 3 amyoglycoside(capreomycin, kanamaycin,amikacin) MDR 50 XDR 5 12HIV perfect storm M tuberculosism africanumm bovism microtim canetti ] 6/23
7 18BCG 1921 Mycobacterium bovis() 19 D 20. D HIV transcript signature 27sodium hydroxide 28LED 29 30MDRXDR LPAs(line probe assay) 31LPAs GenoType MTBDRplus GenoTypeMTBDRsl 32 33Xpert MTB/RIF assay 2 rifampicin 99.2% M tuberculosisbcg mycobacteria 36Quanti-FERON T-SPOT 37 38Quanti-FERON T-SPOT diarylquinolonenitroimidazole 41motifloxacingatifloxacin WHO rifampicin HRZE 4 HR 44 4 HR HRE 45MDR empirical 2HRZES/1HRZE/5HRE 46BCG 47BCG variable 48HIV Nitroimidazole 7/23
8 () Tuberculosis the Lancet, July2, 2011 H23.8 Stephen D Lawn: Alimuddin Zumla HIV HIV 5 4 endemic 100 epidemic 21 Introduction John Bunyan( ) The Captain among these men of death HIV-1 pandemic 21 8/23
9 HIV 5 4 HIV HIV MDR inextricable HIV TNF RA natural resistance-associated macrophage protein1, interferonnitric oxide synthase 2AVitaminD receptor only moderate polymorphism 20 MDRmultidrug resistant XDR (extensively drug resistant) MDR INH rifampicin mycobacterium tuberculosis XDR MDR fluoroquinolone 3 capreomycin kanamycinamikacin MDR 50 XDR 5 MDR 30 primary drug resistance 20 acquired drug resistance 9/23
10 MDR MDR XDR WHO HIV intersection perfect storm KwaZulu Natal province HIV BMI D 2 2 Silicosis 3 40g/ natural resistance-associated macrophage protein1, interferon Nitric oxide synthase 2AVitaminD receptortoll-like receptor TNF 1.5 Mycobacterium tuberculosis M. tuberculosis Robert Koch M. tuberculosis complex M tuberculosism africanumm bovism microti M canetti pasteurisation M bovis 6 M bovis 1921 BCG M tuberculosis acid-fastnonmotilenon-encapsulated non-spore forming bacillus 10/23
11 phenol M tuberculosis acidified organic solvents Nontuberculous mycobacteria Nocardia mycolic acid M tuberculosis 20 M tuberculosis M tuberculosis M tuberculosis 6 Beijing family W W-like family M tuberculosis genome M tuberculosis 10 immunocompetent 90 M tuberculosis macroscopic 20 HIV interferon- T innate immune system M tuberculosis pattern recognition receptors M tuberculosis mannosylated lipoarabinomannnantrehalose dimycolaten-glycolyl muramyl dipeptide 11/23
12 M tuberculosis Cathelicidin LL37 M tuberculosis M tuberculosis D D pleiotropic effect D D D D polymorphism D M tuberculosis T M tuberculosis Mycobacteria epithelioid macrophage T HIV M tuberculosis M tuberculosis M tuberculosis niche M tuberculosis necrosis 12/23
13 HIV HIV M tuberculosis CD4 type-1 cytokine M tuberculosis HIV-1 M tuberculosis M tuberculosis HIV transcriptomics messenger RNA transcriptomic study signature 393 transcript signature 86 transcript signature signature RNAtranscriptional HIV 13/23
14 X point- of- care test 10 WHO bleach sodium hydroxide 13 Ziehl-Neelsen 10 LED (light emitting diodes) 2009 WHO automated liquid culture system WHO WHO 2009 MODSmicroscopically observed drug susceptibility nitrate reductase asssay MDR WHO 2008 LPAs(line probe assays) LPAs GenoType MTBDR plus assay (Hain Lifescience GmbH, Nehren,Germany) 2009 Genotype MTBDRsl assay GenoType MTBDRplus GenoTypeMTBDRsl XDR MDRXDR 14/23
15 lipoarabinomannnann HIV disappointing HIV NAATs : nucleic acid amplification tests NAATloop mediated isothermal amplification NAAT Xpert MTB/RIF assaycepheid, Sunnyvale, CA, USA M tuberculosis rpo B rifampicin 2 rifampicin 1 Xpert MTB/RIF assay M tuberculosis BCG mycobacteria 10 IGRAs in vitro M tuberculosis complex ESAT-6 CFP-10 immunodominant antigen 15/23
16 IGRAs T-SPOT.TB test (Oxford Immunotech, Abingdon, UK) QuantiFERON-TB Gold in tube (Cellestis Ltd, Carnegie, Australia) IGRABCG IGRAs T protein 10interleukin 10monocyte chemotactic protein 1 4 HIV CD4 2, HIV HIV 25 aspiration biopsy initial phase WHO /23
17 regimens 2010 WHO 6 DSTdrug sensitivity test DST MDR default MDR XDR HIV XDR MDR HIV XDR 2008 MDR WHO WHO MDR XDR HIV HIV HIV 2009 HIV 26 HIV 2009 HIV 53 Co-trimoxazole ART CD4 ART CD4 median 25/l ART WHO CD4 HIV 2 8 ART 17/23
18 ARTefavirenz protease inhibitor ART rifampicin rifabutin ART tuberculosis immune reconstitution disease 1695CI self-limiting 3% 10 diarylquinolonetmc-207 mycobacteria ATP synthetase phase2 MDR Nitroimidazoles (PA-824OPC ) Nitroimidazole Motifloxacin, gatifloxacin, TMC WHO Hisoniazid R=rifampicin Z=pyrazinamide E=ethambutol S=streptomycin DOTS=directly observed treatment, short course a rifampicin 2HRZE/4HR ()2 HRZE 4 HR b. continuation phase 2 INH 4 HR HRE 18/23
19 c. intensive phase continuation phase 3 DOTS () 2HRZE/4(HR)3 6 3 DOTS HIV HIV () 2 (HRZE)3/4(HR)3 e. isoniazid rifampicin rapid molecular DST empirical MDR empirical MDR regimen 1 2HRZES/1HRZE/5HRE f. WHO, Standard treatment regimens Isoniazid(H) 5 (4-6)mg/kg, (8-12)mg/kg, 900 / Rifampicin (R) 10 (8-12)mg/kg, (8-12)mg/kg, 600 / Pyrazinamide(P) 25 (20-30)mg/kg, 3 35 (30-40)mg/kg Ethambutol(E) 15(15-20)mg/kg 3 30(25-35)mg/kg Streptomycin(S) 15(12-18)mg/kg 3 15(12-18)mg/kg 1000mg 60 50kg mg/kg 19/23
20 BCG % BCG 10 variable M tuberculosis Mycobacterium vaccae (vaccae ) 3 HIV BCG M vaccae BCG 1993 WHO DOTS (Directly Observed Therapy-Short Course) DOTS STOP TB Strategy Global Plan to Stop TB( ) HIV MDR /100 / HIV MDR 1991 WHO Millenium Development Goal6 (MDG6) /23
21 DOTS Global Plan to Stop TB HIV DOTS 4 INH IPTisoniazid preventive therapy ART 4 ART HIV INH IPT 0.2 WHO Is INH IPTintensified case findingsinfection control 3 ART HIV DOTS HIV 6795CI ART CD4 3I ART Global Plan to Stop TB /23
22 the Lancet, 1. 4/ HIV 5 HIV DM 3 6. HIV 7. RA TNF D 9MDRmultidrug resistant INH rifampicin 10XDR fluoroquinolone 3 amyoglycoside(capreomycin, kanamaycin,amikacin) MDR 50 XDR 5 12HIV perfect storm M tuberculosism africanumm bovism microtim canetti 18BCG 1921 Mycobacterium bovis() 19 D 20. D HIV transcript signature 27sodium hydroxide 28LED 29 30MDRXDR LPAs(line probe assay) 22/23
23 31LPAs GenoType MTBDRplus GenoTypeMTBDRsl 32 33Xpert MTB/RIF assay 2 rifampicin 99.2% M tuberculosisbcg mycobacteria 36Quanti-FERON T-SPOT 37 38Quanti-FERON T-SPOT diarylquinolonenitroimidazole 41motifloxacingatifloxacin WHO rifampicin HRZE 4 HR 44 4 HR HRE 45MDR empirical 2HRZES/1HRZE/5HRE 46BCG 47BCG variable 48HIV Nitroimidazole 23/23
(1) 5 (2) VNTR IS6110RFLP, VNTR35loci JATA(12) JATA(12) MIRU(12) Supply(15) (3) INH inha 22 (4) 5 5 INH RFP 95% 90% 90% 11 (5) 5
(1) 5 (2) VNTR IS6110RFLP, VNTR35loci JATA(12) JATA(12) MIRU(12) Supply(15) (3) INH inha 22 (4) 5 5 INH RFP 95% 90% 90% 11 (5) 5 (6) 30-50 2006 MDR 97 XDR 43.3 15-optimized MIRU VNTR 17 gralnulysin 15k
More information*第94回日本結核病学会_抄録集_全頁.indd
217 R 01 R 02 3 NHO 2010 1 2017 12 8 22 IGRA 9 13 18 56 20 15 4 12 10 IGRA 18 15 1 2 18 9 9 12 RFP 1 1 2015 7 2018 6 329 42 18 24 21 74 20 33 13 11 9 27 9 3 1 29 1 2 4 24 18 18 24 9 7 INH 8 RFP 2 1 HREZ
More informationA B 1.A B A B 2.A B A B 3.A
1 1. 2.WHO 3. 4. 5. 2 2.0mg/kg / 1. 2. 3. 4. 5. 3 1. 90 2. 3. 4. 5. 4 1. 2. 3. 4. 5. 1 21 5 1. 2. 2050 61 3. 1 4. 5. 6 1. ----------- 2. ---- 3. ------ 4. -------- 5. --------- 7 A B 1.A B------------------A
More information11月/庵原俊昭
Shigetaka KATOW 1 1 2 2 3 1 1 1960 5 10 1 8 1 1 1 6 Irtyersenu BC600 2009 1 9,000 2 2008 2 2009 1 AD1 50 DNA 0100-0006 - - RIKEN Center of Research Network for Infectious Diseases (Yurakucho-Denki Bldg.
More information26 No.36 2001.1
No.36 2001.1 25 26 No.36 2001.1 No.36 2001.1 27 28 No.36 2001.1 No.36 2001.1 29 30 No.36 2001.1 No.36 2001.1 31 32 No.36 2001.1 No.36 2001.1 33 Mycobacterium bovis 34 No.36 2001.1 No.36 2001.1 35 36 No.36
More information結核の接触者健康診断の手引き(改訂第4版)
2022 22 4 990-0031 FAX 023-641-7486 19 4 2007 4 18 19 7 2007 7 19 6 7 0308001 6 15 20 6 2008 6 1) 20 9 7 0907001 10 1 2) 4 3) QFT 4) QFT QFT 22 6 2010 6 QFT QFT QFT-3G QFT QFT window period QFT QFT X 19
More information病院感染対策ガイドライン(結核症)
1 11. 2 Abe C, Hirano K, Wada M, et al. Resistance to Mycobacterium tuberculosis to four first line antituberculosis drugs in Japan, 1997. Int J Tubercle Lung Dis 2001;5:46-52. 3 CDC : Guidelines for Preventing
More informationl Fig. 1
TB TB l Fig. 1 Fig. 2TB l l Fig. 3 l Fig. 4 Fig. 5 Fig. 6 M.tuberculosis Fig. 7 Mycobacterium tuberculosis TB Mycobacterium tuberculosis TB Mycobacterium tuberculosis Mycobacterium tuberculosis Mycobacterium
More information8 20 symptom free 2 NEJM Clinical Practice fluticasone 1 2 fluticasone IgE 100U/ml 1819 Bostock 1 A Mycobacterium Toxoplasma
The Lancet, vol 378, Dec.17/24/31,2011 Alexander N Greiner USA Peter W Hellings, Guiseppina Rotiroti Glenis K Scadding The Lancet, Dec. 17/24/31, 2011 http://www.allergy.go.jp/allergy/guideline/04/index.html
More informationMicrosoft Word - ②(添付資料)家庭の夏期節電実態調査の結果について
CO 2 1. 2012 CO 2 CO 2 CO 2 2. 2012 9 28 10 1 8,241 CO 2 3. (1) 2012 2.7%CO 2 1% 1 2 5.8% 3.7% (2.8%)(2.8%) 6 4 5% 1 3 7 5%3 (2) 2012 32%2011 21 (39%)(38%)(37%) 8 2011 (+17.9 ) (+11.9 )(+9.3 )2012 8 (-14.9
More information免疫Ⅱ
100 100 100 1990 127 DNA DNA DNA DNA hybridization DNA RNA DNA DNA 128 12 µδγαε 129 300 1,200 500 50012 4 24,000 1,20024,000 2.910 7 10 8 rejection major histocompatibility complex MHC MHC MHC 130 MHC
More informationbc0710_010_015.indd
Case Study.01 Case Study.02 30 Case Study.05 Case Study.03 Case Study.04 Case Study.06 Case Study.07 Case Study.08 Case Study.21 Case Study.22 Case Study.24 Case Study.23 Case Study.25 Case Study.26
More informationKey words : Adverse reactions, Egg allergy, IgG antibody, Mills allergy, FAST
Key words : Adverse reactions, Egg allergy, IgG antibody, Mills allergy, FAST 13) Danaeus, A., Johansson, S. G. O., Foucard, T. & Ohman, S.: Clinical and immunogical aspects of food allergy in childhood.
More informationBMI BMI
() () 2 QOL () () QOL 11 6 14 20 13.9 20 BMI 12 70 40 11 6 14 20 13.9 20 BMI 12 70 40 57.1 100 ) 1 100 1 250 11 11 430 315 73.3 494 247 50.0 322 60 18.6 12 70 62 88.6 100 18 57.1 1 100 1 250 430 315 73.3
More informationuntitled
1988 2000 2002 2004 2006 2008 IFN Lamivudine Adefovir Entecavir 1 Total number 560 Sex (male/female) 424/136 Age (years)* 38 (15-68) Duration of treatment (weeks)* 26 (1-592) Follow-up time (years) 75(05-21
More information051
Aug. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 4 389( 15 ) 1. MDS collagenase 2. 1 3. 4. / 390( 16 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 4 Aug. 4 4 2004 10 2 1 NTT Aug. THE JAPANESE JOURNAL OF ANTIBIOTICS
More information結核菌/非結核性抗酸菌に対する易感染性とIL-12/IFN-γ経路
IL-12/IFN- BCG IFN- IL-12/IFN- IL-12/IFN- IL-121IL12RB1 - BCG -12 The Interleukin-12/Interferon- Pathway and Susceptibility to M. Tuberculosis and Nontuberculous Mycobacteria Koichi Kusuhara, Hidetoshi
More informationE Societe de Pathologie Infectieuse de Langue Francaise (, 1991) E Spanish Thoracic Society (1992) E American Thoracic Society (ATS : 1993. ü ù2001 ) E British Thoracic Society (1993, ü è2001 ) E Canadian
More informationuntitled
26 2014 3 25 26 3 990-0031 FAX 023-641-7486 990-8570 FAX 023-625-4294 19 4 2007 4 18 19 7 2007 7 19 6 7 0308001 6 15 20 6 2008 6 19 9 7 0907001 10 1 4 QFT QFT QFT 22 6 2010 6 QFT QFT QFT-3G QFT QFT window
More information16 9 Paula TFC BMI PSL hydroxysteroid dehydrogenase (11 -HSD) modulator ( prereceptor mod
Glucocorticoid-Induced Bone Disease (Clinical Practice) NEJM, July 7, 2011 Robert S. Weinstein, M.D. NEJM July 7 2011 Clinical Practice Glucocorticoid-Induced Bone Disease Arcansas Robert S. Weinstein,
More informationProviding Care for HIV-infected Woman Amneris E. Luque, MD SMH AIDS Center Medical Director 2002/07/01
Providing Care for HIV-infected Woman Amneris E. Luque, MD SMH AIDS Center Medical Director 2002/07/01 8000 6000 4000 2000 0 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 30 25
More informationBAANs理論に基づく保健指導プログラム暫定版
WHO 4 5 10% L- -3 RNA L - 1960-3 RNA mrna Bio Activating Advanced Nutrients BAANs BAANs BAANs BAANs L- (NO) -3 EPA, DHA) RNA RNA DNA TNF- PAI-1 ( ) BAANs 40 50% 20% 1Kg 7,000Kcal 50Kcal 11 50Kcal
More information13教員表1.ai
2014 80.8 % http://www.kals.jp/ 02 POINT 1 POINT 2 POINT 3 POINT 4 POINT 5 03 04 2013 2014 10 11 12 1 2 05 3 4 5 6 7 06 25 SCHOOLING 10 21 17 16 14 12 12 12 5 07 28 16 28 16 27 16 13 08 Model Course 1
More informationOriginal Article Abstract Key words
Original Article Abstract Key words Original Article Abstract Key words Case Report Abstract Mycobacterium tuberculosis Key words Field Activities Abstract Key words The 78th Annual Meeting Special Lecture
More information(2009) 1... / 1 ( ) / 1 ( ) / 1 ( ), 2 ( )
212009................................................ 2............................................ 115 (2009) 1... / 1 ( )........................................... 4 2... / 1 ( )......................................
More information日本消化器外科学会雑誌第29巻第9号
Table 1 Oligonucleotide primers used for RT-PCR and internal probes used for Southern blot hybridization Cytokine Primer Sequence (5'-3') 5' 3' Internal probe s' 3' Internal probe 5' 3' Internal probe
More informationuntitled
ORYZA POLYAMINE ORYZA POLYAMINE -P -PC -LC 1. Ver.1.0 MM ver. 1.0MM 1) Roseeuw D.I. et al., Epidermal keratinocytes actively maintain their intracellular polyamine levels. Cell Tissue Kinet. 16, 493-504
More information2001 2003 2005 2006 2007 2008
2001 2003 2005 2006 2007 2008 60 etc. http://nosmoke.hp.infoseek.co.jp/yuugaibussitu.htm http://nosmoke.hp.infoseek.co.jp/yuugaibussitu.htm 23.5% 2.8% 2.8% 3.4% 30.3% 9.9% 11.5% 15.8% AAN 65
More information表1.eps
Vol.1 C ontents 1 2 cell-free EMBO J Proc. Natl. Acad. Sci. USA NatureEMBO J 3 RNA NatureEMBO J Nature EMBO J 4 5 HCV HCV HCV HCV RNA HCV in situ 6 7 8 Nat Struct Mol Biol J Biol Chem Nat Commun J Virol
More informationKekkaku Vol. 81, No. 9: , 2006
Kekkaku Vol. 81, No. 9: 551-558, 2006 Identification of Mycobacteria/Y. Kazumi et al. 557 1 ) Tortoli E, Bartoloni A, Bottger EC, et al. : Burden of unidentifiable mycobacteria in a reference laboratory.
More information19 8 1970 20 10 4 1
19 8 1970 20 10 4 1 IgE 1960 % 1970 20%, 1990 40% 1998 70% 20 IgE 21 90% IgE IgE (%) 70 60 50 40 30 20 10 0 1970 1975 1980 1985 1990 1995 2000 2005 1. 2005 10 2 30 IgE 2. 3 1. B IgE T IgE IgE IgE 2 T IgE
More informationJpn.J.Leprosy 67, (1998)
Jpn.J.Leprosy 67,287-291(1998) Fig.1. Macroscopic appearance of the cultured slides stained by the Ziehl-Neelsen method. Up to bottom: kept at 4 C, 18 weeks, cultured for 6 weeks, 8 weeks, 10 weeks, 12
More information特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書(案)
VOL.51 NO.6 JUNE 2003 JUNE 2003 9) Niederman MS et al: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention.
More informationコロイド化学と界面化学
x 25 1 kg 1 kg = 1 l mmol dm -3 ----- 1000 mg CO 2 -------------------------------------250 mg Li + --------------------------------1 mg Sr 2+ -------------------- 10
More informationFig. 1 Trends of TB incidence rates for all forms and smear-positive pulmonary TB in Kawasaki City and Japan. Incidence=newly notified cases of all fo
Kekkaku Vol. 79, No. 1: 17-24, 2004 17 (Received 21 Aug. 2003/Accepted 18 Nov. 2003) Fig. 1 Trends of TB incidence rates for all forms and smear-positive pulmonary TB in Kawasaki City and Japan. Incidence=newly
More information<B54CB5684E31A4E9C0CBA4E5AA6BC160BEE3B27AA544A5552E706466>
N1 2 3 1 16 17 18 19 20 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 4 2 38 39 40 41 42 44 45 46 47 48 50 51 52 53 54 55 56 57 58 59 60 61 5 3 62 63 64 65 66 68 69 70 70 72 74 75 76 77 78 80 81 82 83
More information広島県獣医学会雑誌24号.indd
1 1 Study on the effects of dexamethasone administration in acute coccidiosis accompanied by bloody stools TOMOYASU KUROSE Shoubara Veterinary Clinical Center, P. F. A. M. A. A -1-, Nishihonmachi, Shoubara,
More informationKekkaku Vol. 59, No8 STUDIES ON THE ORIGIN AND CLINICAL SIGNIFICANCE OF SMEAR-POSITIVE AND CULTURE-NEGATIVE TUBERCLE BACILLI Michio TSUKAMURA* and Har
Kekkaku Vol. 59, No8 STUDIES ON THE ORIGIN AND CLINICAL SIGNIFICANCE OF SMEAR-POSITIVE AND CULTURE-NEGATIVE TUBERCLE BACILLI Michio TSUKAMURA* and Haruo TOYAMA (Received for publication April 4, 1984)
More information_02三浦.indd
36, 7-11, 2016 IPD PCV 5 3 80% 1 invasive pneumococcal disease ; IPD 2010 7 PCV7 2013 13 PCV13 IPD IPD 2,3 2015 1 2015 12 5 1 IPD 2015 1 12 IPD 5 IPD 1 4 2 5 http://pneumocatch.jp/ 5 Statens Serum Institut
More informationDIC vegetation 1 nonbacterial thrombogenic e
2001 2002 Guidelines for the Prevention and Treatment of Infective Endocarditis (JCS 2003) h 1 1 2 3 4 5 6 7 8 9 2 1 2 3 1 2 3 4 1 2 5 1 2 1 G Streptococcus viridans Streptococcus bovis 2 G Streptococcus
More informationuntitled
HCV 150 HCV 13 3 13 4 13 8 14 2 14 2 14 8 15 3 15 8 17 3 7 8 18 3 ----- i Q1 1 Q2 1 Q3 1 Q4 2 Q5 3 Q6 3 Q7 3 Q8 4 Q9 4 Q10 : 5 6 Q1 6 Q2 7 Q3 7 8 Q4 8 Q5HCV 8 Q6HCV 9 Q7HCV 9 Q8NAT 10 Q9 10 Q10 11 Q11
More informationNo. 432 May BP MOT MOT 2
NO.432 May 2008 2 3 4 Pathway to Global Edge -vol.2 Global Edge Institute 6 3 7 10 GP 12 Sustainable Engineering Program 14 16 17 20 18 202 19 20 20 No. 432 May 2008 2004 196540 1967 1971 BP 11 2002 2003
More information10 2 2 10 6.5 78 1 65 / 30 / - 2 -
- 1 - 10 2 2 10 6.5 78 1 65 / 30 / - 2 - 3 3 30 8 4 8 6 11 14 45 14 7 8 1-3 - 4 1 () 20 4 9 4 9 3 9 4 PR 4 3-4 - - 5 - PR 15 4 PR 7 8 4 9 10-6 - 9 10 9 10 4 9 10 3 9 10 9 9 9 10 PR 1-7 - PR - 8 - 30 100-9
More information結核(セミナー)改訂版 The Lancet, Aril 20, 2019
結核 ( セミナー ) 改訂版 The Lancet, Aril 20, 2019 僻地で世界最先端 西伊豆健育会病院西伊豆早朝カンファランス R1. 7 Tuberculosis (Seminar) 著者 Jennifer Furin MD, Department of Global Health and Social Medicine, Harvard Medical School Helen
More informationPowerPoint Presentation
DNA 87 ( ) Nucleic Acids ResearchDB RNA 29 94 58 29 18 43 153 : 511 Bio DB Catalog (DBCAT) http://www.infobiogen.fr/services/dbcat/ 2 GenBank MB SRS) DAS) 3 4 5 A A A 6 OGSA-DAI 7 9 DB Medical Encyclopedia
More informationTable 1 Characteristics of the study participants in Imari municipal hospital
Key words: tuberculosis, booster phenomenon, two-step tuberculin test Table 1 Characteristics of the study participants in Imari municipal hospital Fig. 1 Frequency distributions of size of the first tuberculin
More information*...C
J Health Care Dent. 2004; 6: 23-41 Printed in Japan. All rights reserved * Reconsideration of Diagnosis, Treatment and Maintenance of Periodontal Disease Periodontitis is different from other infectious
More information【知事入れ版】270804_鳥取県人口ビジョン素案
7 6 5 4 3 2 1 65 1564 14 192 193 194 195 196 197 198 199 2 21 22 23 24 1.65 1,4 1.6 1,2 1.55 1, 1.45 6 1.5 8 1.4 4 1.35 1.3 2 27 28 29 21 211 212 213 214 6 5 4 3 2 1 213 218 223 228 233 238 243 248 253
More informationDNA
1 1 1. 1 2. 2 3. 2 4. 2 2 1. 2 4 5 7 2. 7 3. DNA 8 4. 10 13 Plasmodium (P. falciparum) (P. vivax) (P. malariae) P. ovale 4 40% 200 7 40 48 72 1. - 1 - 2. DNA 3 3. 1) 2) 3) 4) 4. 1 1) - 2 - 2) EDTA 1) 1
More information振動充填燃料の粒子焼結試験実施計画書
C JNCTJ8410 2004-006 2004 3 ( ) UPRISE Nd 250mL 0.2 mol Nd Nd (FP)DF DOBA DOiBA NN'-2--1.6 mol/l NN'- -1.7 mol/l NN'-1.5 mol/l DOBA 1mol/L 3.5mol/L 2 NN'--1.7 mol/l NN' -1.5 mol/l ZrRu Ce DF 150 100 Sr
More information2009年度 東京薬科大学 薬学部 授業計画
2009 2 234 Tokyo University of Pharmacy and Life Sciences since 880 Tokyo University of Pharmacy and Life Sciences Department of Clinical Pharmacy Men's Division Department of Clinical Applied Pharmacy
More informationCandida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents
D 012 Candida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents DATA : 1 DATA : 2 3 DATA : UNGITEC 1 1 DATA : 20pg/mL 1020pg/mL 10pg/mL (cut off 20pg/mL) 90.2%(37/41) 100%(85/85) 96.8%(122/126)
More informationNo21Vol1.indd
( ): - PSA Shojiro Kano Head, Working Group of PSA Testing Standardization Committee (PSA) PSA PSA JCCLS PSA A PSA B PSA PSA Wang PSA FDA Hybritech Tandem-R PSA PSA PSA PSA - (ACT) - (AMG) ACT (PSA-ACT)
More informationP.01 C Global Value Corp. PAT.P 2008'
Value Point system *1 2009. 2. 25 2009. 2. 25 C Global Value Corp. PAT.P 2008' P.01 C Global Value Corp. PAT.P 2008' C Global Value Corp. PAT.P 2008' P.03 P.06 C Global Value Corp. PAT.P 2008' C Global
More information日本化学療法学会雑誌第59巻第6号
P P Streptococcus pneumoniae S. pneumoniae Key words Streptococcus pneumoniae Fig. 1. Capsular swelling reaction of S. pneumoniae type 6B. Cells are stained dark blue using a methylene blue. Capsule is
More information/
333 344 / 332 03-6264-066003-6264-0663 03-6264-0620 334 LAL 335 336 LAL 338 QCL-1000 LAL 33 LAL 340 C 341 LAL 343 ELx808 344 FLx800 345 PyroTec 346 WinKQCL 347 CSE 348 / 03-6264-066003-6264-0663 03-6264-0620
More informationuntitled
January 2009 Rotor-Gene Q Sample & Assay Technologies 1 1-1 1.1 1-1 1.2 Rotor-Gene Q 1-1 1.3 Rotor-Gene Q 1-1 1.4 1-1 2 2-1 2.1 Run File 2-1 2.2 2-2 2.3 2-2 2.4 PCR 2-3 2.5 2-3 2.6 2-4 2.7 2-4 2.8 2-5
More informationインターフェロン γ 遊離試験を用いた結核感染対策 -IGRA を用いた結核感染対策 - 潜在性結核感染症結核菌は空気感染 ( 飛沫核感染 ) により, 肺に侵入し感染が成立するが, 感染者の多くは, 感染巣で結核菌の増殖が封じ込められ, 結核菌が持続生残菌 (persister) となりすぐには結
[ 解説 ] インターフェロン γ 遊離試験を用いた結核感染対策 IGRA を用いた結核感染対策 Tuberculosis infection control by using interferon-γ release assay -TB infection control by using IGRA- 西村知泰 森 正明 慶應保健研究,32(1),113-117,2014 要旨 : 未だ, 日本は結核
More informationMicrosoft Word - H22年度雄勝中央病院卒後臨床研修プログラム.docx
3 2 380 32 1 202,812 11,967 17.2 1,441 129 24 1 6 1 3 1 2 3 50-60 /2 2 2 1-2 2 1 2 2 1 1-2 1 CPC / 4 / / 2 / AED ICLS JPTEC 3 a: b: c: d: 4 c,d a b d 70% 2 10 4 11 12 21 7 21 8 5 Evidence Based Medicine
More informationMicrosoft Word - TIP2006-3-TGN doc
TIP 2006 3 Vol 21 No3 p21-24 TGN1412 I NPO 3 13 15 [1,2] I TGN1412 18 40 1 ICU 19 6 4 3 [3] The Medicines and Healthcare Products Regulatory Agency MHRA [2] TGN1412 TGN1412 CD28-SuperMAB T TGN1412 T superagonistic
More informationCHEMOTHERAPY Fig. 1 Chemical structure of TE-031
CHEMOTHERAPY Fig. 1 Chemical structure of TE-031 CHEMOTHERAPY Table 1 Experimental groups for active systemic anaphylaxis in guinea pigs : Single dosage Fig. 2 Schedule for active systemic anaphylaxis
More information13●53頁●6-7▲院内感染対策▲.ppt
No.610 1 No.121 2 No.128 Nosocomial infection, Hospital-acquired infection CDC nosocomial infection, hospital-acquired infection nosocomial nosokomeion hospital nosocomial infection nosocomial pneumonia
More information703 Kekkaku Vol. 85, No. 9 : 703_709, 2010 Line Probe Assay による Rifampicin 耐性遺伝子検査の 有用性 患者喀痰を供試しての検討 稲垣 1, 6 森山 1, 3, 4 孝行 誠 八木 哲也 3 打矢 恵一 5 市川 和哉 3 二
73 Kekkaku Vol. 85, No. 9 : 73_79, Line Probe Assay による Rifampicin 耐性遺伝子検査の 有用性 患者喀痰を供試しての検討 稲垣, 森山, 3, 4 孝行 誠 八木 哲也 3 打矢 恵一 5 市川 和哉 3 二改 俊章,, 中川 拓 小川 賢二 要旨 緒言 薬剤耐性結核の蔓延防止は 臨床上重要な課題である そこで 早期に RFP 耐性を検
More informationCHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of BRL 28500 against standard strains of bacteria Fig, 1 Sensitivity distribution of ABPC-resistant E. coli isolated from urinary tract Fig. 2 Sensitivity
More informationサイトメトリー12-1.indd
Cell Growth Inhibition and Apoptosis in Cancer Cells Kazuki Omoteyama, Shoichi Inoue and Alaa-eldin Salah-eldin Department of Environmental Medicine and Informatics, Graduate School of Environmental Earth
More information受精着床学会-04-プログラム-世界.indd
世 界 体 外 受 精 会 議 記 念 賞 候 補 演 題 プログラム 世 界 体 外 受 精 会 議 記 念 賞 候 補 演 題 ( 基 礎 ) 9 15 9:00 10:00 1-1 1 2 3 1,3 1 Dieter Egli 3-2 -3 versican 1 2 3 1 1 2 1 1 1 1 3-4 mir-100 1 2 1 1 1 2 1 1-5 -6 33 世 界 体 外 受
More information2.
2. 10 2. 2. 1995/12006/111995/42006/12 2. 10 1995120061119954200612 02505 025 05 025 02505 0303 02505 250100 250 200 100200 5010050 100200 100 100 50100 100200 50100 10 75100100 0250512 02505 1 025051205
More informationFig. 1 Chemical structure of DL-8280
Fig. 1 Chemical structure of DL-8280 Fig. 2 Susceptibility of cl in ical isolates to DL4280 Fig. 5 Susceptibility of clinical isolates to DL-8280 Fig. 3 Susceptibility of clinical isolates to DL-8280 Fig.
More information< > Introduction to Basic Physical Chemistry 1,2 2 [ advanced [ [ [ [ [ KULASIS
< > Introduction to Basic Organic Chemistry 1,2 [ 2 [ 10 11 12 13 14 15 [ [ [ [ KULASIS < > Introduction to Basic Physical Chemistry 1,2 2 [ advanced [ 11 12 14 15 [ [ [ [ KULASIS < > Introduction to Basic
More information損保ジャパンの現状2011
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 62 63 64 65 66 67 68 69
More informationROCKY NOTE 結核に対する結核菌 LAMP 法の検査特性 (150226) 肺炎の治療の前に喀痰の検査を施行 これを機会に結核菌 LAMP 法の検査特性について調べ てみることにした 比較的新しい論文を
結核に対する結核菌 LAMP 法の検査特性 (150226) 肺炎の治療の前に喀痰の検査を施行 これを機会に結核菌 LAMP 法の検査特性について調べ てみることにした 比較的新しい論文を簡単に流し読みしてみることにした 文献 1 では感度が 98% 特異度が 78.3% と記載されている real-time fluorescence quantitative PCR (Q-PCR). の感度が 96.0%
More informationindd
Molecular Targeted Therapy for Lung Cancer from a Pharmaceutical Point of Viewe Naho SASAKI epidermal growth factor receptor tyrosine kinase inhibitor :EGFR-TKI vascular endothelial growth factor:vegf
More information医療レーザー脱毛の威力と限界
.... mm. CT WH W H W H W H... kcalkcal. 1. cal kcal 1 6 2 3. 4. 5. 1 6 6. B6 B12 B. BMI BMI30 C. D. kg mm . CT WH W H W H W H... kcalkcal . 1. cal kcal 1 6 2 3. 4. 5. 1 6 6. B6 B12 B. BMI BMI30 C. D.
More information17. (1) 18. (1) 19. (1) 20. (1) 21. (1) (3) 22. (1) (3) 23. (1) (3) (1) (3) 25. (1) (3) 26. (1) 27. (1) (3) 28. (1) 29. (1) 2
1. (1) 2. 2 (1) 4. (1) 5. (1) 6. (1) 7. (1) 8. (1) 9. (1) 10. (1) 11. (1) 12. (1) 13. (1) 14. (1) 15. (1) (3) 16. (1) 1 17. (1) 18. (1) 19. (1) 20. (1) 21. (1) (3) 22. (1) (3) 23. (1) (3) 24. 1 (1) (3)
More informationDynalTransplantDiagnostic.indd
2011 1 SeCore HLA SBT 1 2 AllSet + Gold SSP HLA 7 3 SSP UniTray HLA 11 4 27 5 32 ii 1 SeCore HLA SBT SeCore 2 SeCore HLA SBT SeCore 3 SeCore 4 HLA-I 5 HLA-II 5 utype 5 GSSP 6 1 SeCore HLA SBT Sequencing
More informationFig.1 Procedures of the spot tests for the detection of serum HBV-DNA
Key words: HBV DNA, HBV carrier, HBeAg Fig.1 Procedures of the spot tests for the detection of serum HBV-DNA 昭 和61年2月20日 87 Table 1 Comparison of HBeAg/anti-HBe Fig.2 Comparison of the sensitivity of the
More informationKey words: atypical pulmonary mycobacteriosis, Mycobacterium avium complex, bronchial washing, transbronchial lung biopsy Table 1 Background data of 14 patients Old pul. tbc: sclerosing pulmonary tuberculosis
More informationKey words: Streptococcus pyogenes, Streptococcus dysgalactiae subsp. equisimilis, rapid diagnosis
Key words: Streptococcus pyogenes, Streptococcus dysgalactiae subsp. equisimilis, rapid diagnosis Table 1 Strains evaluated Table 3 Comparison of sensitivity (CFU/mL) of 8 rapid diagnostic kits for detecting
More informationCytokine-adsorbing hemofilter:バクスター セプザイリス(AN69ST膜hemofilter)
Cytokine-adsorbing hemofilter AN69ST hemofilter Acute Care Kazuhiro MORIYAMA, Noriko ONOZUKA, Hidehito TSUNASHIMA 1. はじめに 1) CRRT AN69ST 2) sepxiris 2014 7 1 2 AN69ST 2. AN69 膜の開発経緯 1960 1969 著者連絡先 Acute
More informationVOL.39 S-3
VOL.39 S-3 CHEMOTHERAPY SEPT.1991 Table 1. Background of characteristics and allocation of 5 healthy male volunteers in a multiple-dose study on panipenem/betamipron Day 1 Fig. 1. Schedule of multiple-dose
More informationuntitled
1 2 3 4 5 6 7 8 9 10 11 12 13 µ µ µ 14 15 16 17 1. Fabris P, Betterle C, Floreani A, Greggio NA, de Lazzari F, Naccarato R, Chiaramonte M: Development of type 1 diabetes mellitus during interferon alfa
More information